# Improving Appropriate Management Of Chemotherapy Drugs In Paediatric Oncology, Hospital Tunku Azizah

JABATAN FARMASI, HOSPITAL TUNKU AZIZAH (HTA)

### **ADVISOR**



### Yam Chiew Fong

Ketua Jabatan Farmasi Hospital Tunku Azizah

### ONCOLOGIST



**Dr. Zulaiha Bt Muda** Consultant Hemotologist Oncologist



### **Noraini Bt Mohamad** Timbalan Pengarah Farmasi Hospital Kuala Lumpur



**Dr. Teh Kok Hoi** Pediatric Hemoto-Oncologist

### FACILITATOR



Dr. Farizan Bt Abdul Ghaffar



NURSE

Muzlinihaiyu Bt Mad Lazim



Nursyamsurya Bt Iberahim



Marlina bt Rosman

### **PHARMACIST**







Dr. Rizal Husaini B. Razali



Radhika A/P T Sathya Narayana









Siti Syahirah Alyaa Bt Saidi

# Selection Of Opportunities For Improvement



# **PROBLEM IDENTIFICATION**

Problem No. High incidence of leaking or spillage for chemo preparations 1 Large number of wastage on reconstituted chemotherapy drugs 2 among oncology patient Low percentage of appropriate management of chemotherapy 3 drugs in paediatric oncology Incidence of long waiting time on receiving chemotherapy 4 prescriptions from gynaeoncology ward Incidence of long waiting time on confirming preparation for 5 Intravitreal Topotecan and Melphalan among ophthalmology patient



# **PROBLEM VERIFICATION**

No.	Problem	Problem Verification				
1	High incidence of leaking or spillage for chemo preparations	<b>0.7%</b> of reconstituted chemo preparation were leaking during counterchecking process or administrating in the ward from February 2023 to July 2023.				
2	Large number of wastage on reconstituted chemotherapy drugs among oncology patient	<b>2.1%</b> reconstituted chemotherapy drugs were wasted from February 2023 to July 2023.				
3	Low percentage of appriopriate management of chemotherapy drugs in paediatric oncology	Average <b>23.6%</b> incidence of inappropriate management of chemotherapy drugs from February 2023 to July 2023.				
4	Long waiting time on receiving chemotherapy prescription from gynaeoncology ward	<b>4.1%</b> Of chemotherapy prescription was received after 10 am February 2023 to July 2023.				

Long waiting time on confirming 5 for Intravitreal preparation and Melphalan Topotecan among ophthalmology patient

Discussion was carried out with radiologist and 6.7% case need to wait for confirmation ophthalmologist on the timing of ordering on preparation of Intravitreal Topotecan Topotecan and Melphalan before carrying out and Melphalan from February 2023 to July procedure. 2023. 5

### Solution

Product complaints on sodium chloride drip were reported to NPRA and respective company. Respective company was implementing several action to improve the quality of drip.

Discussion was carried out with doctors. Doctors will inform pharmacists about the cancellation on chemo preparation as earlier as possible.

QAQI project is planned to improve this problem.

Discussion was carried out with doctors and clinical pharmacists. A media (What'sapp group) was created among clinical pharmacists and staff nurse to update CDR pharmacy on the addition of chemotherapy.

# **PROBLEM PRIORITIZATION**

PROBLEM	S	Μ	Α	R	Т	Total
High incidence of leaking or spillage for chemo preparations	33	29	33	25	28	148
Large number of wastage on reconstituted chemotherapy drugs among oncology patient	33	30	33	28	25	149
Low percentage of appropriate management of chemotherapy drugs in pediatric oncology	33	33	33	33	33	165
Incidence of long waiting time on receiving chemotherapy prescription from gynaeoncology ward	30	25	33	23	28	139
Incidence of long waiting time on confirming preparation for Intravitreal Topotecan and Melphalan among ophthalmology patient	30	28	33	29	25	145
Rating Scale: 1 – Low to 3 – High						6

Kating Scale: 1 – Low to 3 – High Results were obtained from nominal group technique among 11 members.



# **PROBLEM TO BE STUDIED**

# Low Percentage of **Appropriate Management of Chemotherapy Drugs In Paediatric Oncology**



# REASON OF SELECTION



# SERIOUSNESS

# **GLOBAL**

### Heike et al., 2019

Total of 406 chemotherapy prescribing errors were intercepted that affected 375 (2%) of the total orders which causes the consequences such as reduced therapeutic efficacy (0.44%), the need for increased monitoring (0.48%), prolonged hospital stay (0.55%), and fatality (0.02%).

### Elsaid et al., 2013

Despite decades of increased knowledge of the toxicities and safety standards of chemotherapy, prescribing errors such as transcription/communication errors and dosing errors in oncology practice continue to be a major issue that causes patient harm.

### Ford et al., 2006

In this paper-based system, errors were classified as either order-writing, dispensing, or administrationrelated.

Chua et al., 2009

Chua et al., 2010 Drug administration errors are as common in paediatric wards in Malaysia as in other countries. The most common types of drug administration errors were incorrect time of administration (28.8%), followed by incorrect drug preparation (26%), omission errors (16.3%) and incorrect dose (11.5%).

**Ong et al., 2013** Dispensing error were wrong diluents/ wrong amount of diluents, exceeding stability time after reconstitution can cause harmful clinical outcomes to patients.



# MALAYSIA

Administration errors are more prevalent in oncology

peadiatric wards since medications are more complex. 10.4% of administration errors were considered as potentially life-threatening.

# SERIOUSNESS

# **GLOBAL**





# MALAYSIA

2009	
on errors are more preva	lent in oncology
vards since medications ar	e more complex.
dministration errors were	e considered as
fe thraataning	1
CV	
	non in paediatric
utcomes	tries. The most
	on errors were
	8%), followed by
	on errors (16.3%)
oring	

Dispensing error were wrong diluents/ wrong amount of diluents, exceeding stability time after reconstitution can cause harmful clinical outcomes to patients.

# **MEDICATION ERROR**

## Incidence of double dose for chemotherapy in oncology ward (2016)





### **ADVERSE EVENTS**

### **Cisplatin toxicity**

- developed acute kidney injury

Vincristine toxicity

- developed neuropathic pain and burning sensation

- given IV Folinic 15mg q3H and Syp Carbamazepine 20mg TDS

### Lomustine toxicity

- severe mucositis on whole throat
- Harm to patient
- Reduce treatment outcome
- Prolong hospitalization
- Increase healthcare cost

# **APPROPRIATENESS**

### Collins, C. M., & Elsaid, K. A., **2011<sup>7</sup>**

Healthcare failure modes and effects analysis revealed hazard scores in the prescribing and administration components in chemotherapy. Computerized Provider A study at French university hospital detected 5.2% of 6,607 chemotherapy errors (91% prescription errors, 8% pharmacological and 1% administration error) but If the

Order 5 0.023

elimir signif

# Improve patient safety and treatment outcome **Reduce hospitalization period** Reduce healthcare cost

Reinhardt, H.et.al, **2019<sup>9</sup>** 

efficacy (0.44%), increased frequent monitoring (0.48%), an extended hospital stay (0.55%), and fatalities (0.02%). Appropriate prescribing by checking the order history, the patient's medical file, and having a thorough understanding of chemotherapy protocols were the most effective methods for error prevention.



### Ranchon, F., et.al, **2011**<sup>8</sup>

would

a cost

# MEASURABLE

Percentage of appropriate management of chemotherapy drugs

Remediable by appropriate strategies change and multidisciplinary approach

# TIMELINESS

Can be completed in a short period of time



# REMEDIABLE

# **PROBLEM ANALYSIS**

# WHAT

**Management of chemotherapy** drug was inappropriate across the process of prescribing, preparing, dispensing and storage of chemotherapy drug.

# WHY

Weakness of system and work process with lack of knowledge and awareness among staff

# WHO

Doctors, Nurses, Pharmacists



### From February 2023 until August 2024





### In Paediatric Oncology ward (10B) in Hospital Tunku Azizah

# HOW

Inappropriate management lead to serious adverse effect among patient and increased healthcare cost

# 

# INTRODUCTION



# The Largest Paediatric Oncology Centre

Treating >30% of all new childhood cancer patients

Training Paediatric Oncology Centre for sub-specialist



# 

Average number of cancer patient admit for chemotherapy per month:

120

month:



### Average number of reconstituted intravenous(IV) chemotherapy drug by CDR pharmacy per



# DAILY WORKFLOW



### Ward

# Prescribing



Specialist/Trainee Subspecialist prescribe chemotherapy manually by using cytotoxic drug reconstitution (CDR) form. UNIT REKONSTITUSI UBAT SITOTOKSIK (CDR) JABATAN FARMASI HOSPITAL TUNKU A717AH

### CYTOTOXIC DRUG RECONSTITUTION REQUEST FORM

N14.5.47			DATE:					
NAME	MYKID/ MYK	MYKID/ MYKAD:						
Please [V]: New case Repeat case				user /				
AGE: 10 SEX: M/F/ V	/T: 14 kg HT:	(02 cm	BSA: 0-62	m <sup>2</sup>				
auce ymphoriai ym	shoma / lenia	entre me	B-proto	=1 $tH$				

No.	Chemotherapy	Dose (/m²)	Dose prescribed (infusion/bolus)	Date of PREPARATION*
,	N martine	Lomp	0-9 mg in 10 ml no	07-119/24 (10B)
2	v daunoubicin	Bomp	18mg in some ars	2-1-1-19/24 2-3-519/24
3.	IM pegaspaseymes	- 2.500 um	1550 unit	04-819124
4.	17 arcihotnescate		12- Song in Smi NB	014 - 1191 -4 035 - 1/10/24
-				

Cytotoxic Drug Reconstitution Request Form (CDR Request Form)

# **In-Patient Prescription**

### **In-Patient Prescription**

Name								Weight										
MyKid / MyKad								Height										
RN BSA																		
				Date														
				Time	Α	В	А	В	А	В	А	В	А	В	А	В	А	E
				6pm														
		HIS																
MO Sign & Chop	Specialist																	

### **Differences:**

- Chemotherapy drug for each regimen
- > Diluent
  - Volume of diluent
  - Infusion hour
  - Date of preparation

Ward

# Reconstituting

### **Process of reconstitution**

Prescribing





**Reconstitute in CLEAN ROOM** 





### **Pharmacist**/ Assistant **Pharmacist:**

- Screen CDR form
- Prepare worksheet, label and chemo bag
- Counterchecking

### **Reconstituted chemotherapy drugs**



### **Staff Nurse:** and Countercheck Collect chemotherapy from pharmacy

Ward





# **CRITERIA for counterchecking:** > Patient's Details

- Reconstituted Chemotherapy drug
- (b) Preparation and expiry date
- (b) Volume of diluent
- (c) Colour and characteristics
- (d) Storage





# **TERMS AND DEFINITIONS**

Include:

- Selection of drugs
- Use of drugs (prescribing, packaging, dispensing and counselling)
- Storage and distribution Among personnel with appropriate skill and attitude

## Chemotherapy Drugs

Management

of Drugs

- Drugs stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Can be given by mouth, injection, or infusion, or on the skin, depending on the type and stage of the cancer

(WHO guide on Drug Management 2004)

(National Cancer Institute)

# **TERMS AND DEFINITIONS**





Volume of infusion Infusion rate Proper monitoring



Sources: WHO guide on Drug Management 2004 & National Cancer Institute

# **IMPORTANT ASPECTS FOR CANCER CHILDREN**





# **PROBLEM STATEMENT**

A survey conducted in February 2023 to July 2023 showed that only 76.4% of incident of appropriate management of chemotherapy drugs in paediatric oncology.

This will cause poor clinical outcomes and increase risk of adverse effects of **chemotherapy** as well as compromising total patient care.

Multiple factors including CDR form is too complicated, lack of knowledge, lack of two-ways communication between health professional, staff fatigue, inadequate counterchecking, wrong details provided and unfamiliar with prescribing method may contribute to this problem.



This study aims to improve the percentage of appropriate management of chemotherapy drugs in paediatric oncology to achieve optimal treatment outcome and reduce healthcare cost.







# PROCESS OF CARE



### **Roles & Responsibilities**

Specialist/ Trainee Subspecialist

Specialist/ Trainee Subspecialist

Pharmacist/ Assistant Pharmacist

> Pharmacist & Specialist

Pharmacist/ **Assistant Pharmacist** 

Pharmacist

Pharmacist

Pharmacist/ **Assistant Pharmacist** 

Trainee Subspecialist



### **Roles &** Responsibilities

Pharmacist

Pharmacist

Pharmacist/ Assistant Pharmacist

Staff Nurse

Staff Nurse / Pharmacist

Staff Nurse/ Doctor

Staff Nurse/ Doctor

Pharmacist

# MODEL OF GOOD CARE



### Criteria

Specialist/trainee subspecialist prescribing chemotherapy

### CDR request form need to be filled by specia

- a) Correct Patient's Details
- b) Correct Regimen
- c) Correct Drug
- d) Correct Dose In Correct Unit (Based On BS
- e) Correct Diluent With Its Volume
- f) Correct Concentration Of Drug
- g) Correct Date Of Preparation

Pharmacist screen on received CDR form wh CDR form with:

- a) Correct Patient's Details
- b) Correct Regimen
- c) Correct Drug
- d) Correct Dose In Correct Unit (Based On B
- e) Correct Diluent With Its Volume
- f) Correct Concentration Of Drug
- g) Correct Date Of Preparation
- h) Presence Of Specialist/Trainee Subspecialist's Cho Signature

Pharmacist screen the CDR request form

1

### Standard

list/trainee subspecialist and	include data:
	100%
	100%
	100%
SA/ Weight)	100%
	100%
	100%
	100%
hether it is a complete	
	100%
	100%
	100%
SA/ Weight)	100%
	100%
	100%
	100%
pecialist's Chop And	100%

No.	Critical step	Criteria	Standar
3	Prepare CDR worksheet, labels and bags	<ul> <li>Pharmacist or Assistant Pharmacist will prepare:</li> <li>CDR Worksheet: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose Of Drug</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>Labels: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>c) Correct Dose</li> <li>d) Correct Patient With Its Volume</li> <li>e) Correct Preparation Date And Expiry Date</li> <li>f) Correct Storage Condition For Reconstituted Chemotherapy Drug</li> </ul> <li>Bags: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Patient's Details</li> <li>c) Correct Patient's Details</li> <li>c) Correct Patient's Details</li> </ul> </li>	100% 100% 100% 100% 100% 100% 100% 100%

### rd

# Countercheck CDR

Pharmacist will counter check on the written criteria on: Prepared CDR Worksheet:

- a) Correct Patient's Details
- b) Correct Drug
- **Correct Dose** C)
- d) Correct Diluent With Its Volume

Prepared Labels:

- a) Correct Patient's Details
- b) Correct Drug
- c) Correct Dose
- d) Correct Diluent With Its Volume
- **Correct Preparation Date And Expiry Date** e)
- Correct Storage Condition Of Reconstituted **f**) Chemotherapy Drug

**Prepared Bags:** 

- a) Correct Patient's Details
- b) Correct Drug
- c) Correct Number And Size Of Bags Required

worksheet, labels and bags

No.

### Standard

100% 100% 100% 100%

100% 100% 100% 100% 100% 100%

100% 100% 100%

36
Pharmacist or assistant pharmacist reconstitute the chemotherapy drug with:

5

6

Chemotherapy Drug Reconstitution

- a) Correct Drug
- b) Correct Volume Of Drug
- c) Correct Volume Of Diluent
- d) Absence Of Leakage Or Impurity

Pharmacist countercheck on the reconstituted chemotherapy drug by checking on:

Countercheck reconstituted drug chemotherapy final and approve preparation

- a) Correct Patient's Details On Label And Bag
- b) Correct Drug
- **Correct Colour And Its Characteristics** C)
- d) Correct Final Volume
- e) Absence Of Leakage Or Impurity
- Presence Of Supplied Administration Set For Specific f) **Chemotherapy Drug**



100% 100% 100% 100%

100% 100% 100% 100% 100% 100%

Νο	Critical step	Criteria
7	Nurse check chemotherapy drug during collection in pharmacy	<ul> <li>Nurse check the reconstituted chemotherap</li> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Colour And Characteristics</li> <li>d) Correct Dose</li> <li>e) Correct Final Volume</li> <li>f) Absence Of Leakage Or Impurity</li> <li>g) Correct Preparation Date And Expiry Date</li> <li>h) Correct Storage Condition</li> <li>i) Presence Of Supplied Administration Second therapy Drug</li> </ul>
8	Administer chemotherapy to patient according to regimen and close monitoring	<ul> <li>Doctors or nurses will administer chemot regimen planned with following criteria:</li> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose And Final Volume Of Reco Drug</li> <li>d) Correct Route Of Administration</li> <li>e) Correct Infusion Rate</li> <li>f) Correct Date And Time Of Administratio</li> <li>g) Close Monitor Patient's Vital Sign And C Chemotherapy</li> </ul>

### py drug for

100% 100% 100% 100% 100% 100%

te

t For Specific

therapy according to the

onstituted Chemotherapy

on Condition During And Post 100% 100% 100% 100% 100% 100%



## KEY FOR **LMPROVEMENT**

## **STUDY OBJECTIVES**

### **General Objectives:**

To improve percentage of appropriate management of chemotherapy drugs in paediatric oncology

### Specific Objectives:

- To determine the percentage of appropriate management chemotherapy drugs in paediatric oncology ward
- 2. To identify the causes that lead to low percentage of appropriate management of chemotherapy drugs
- 3. To formulate and implement appropriate remedial measures
- 4. To evaluate the effectiveness of remedial measures



of

## **INDICATOR AND STANDARD**

INDICATOR	Percentage of appropriate manage
FORMULA	Total Number of Patient wi Management of Chemoth Total Number of Patient on
STANDARD	95%

\*Number of patient is calculated based on each prescribe regimen Prescribing phase: 0.1% - 24.6%, Preparation phase: 0.40% - 0.50%, Dispensing phase: 0.03%, Administering phase: 0.02% - 0.10%<sup>11</sup>



### ement of chemotherapy drugs

th Appropriate erapy drugs Chemotherapy x 100%

## PROCESS OF GATHERING INFORMATION



## METHODOLOGY

Study Design  • Quasi Experimental		
Sampling Technique	<ul> <li>Universal Sampling</li> </ul>	
Sample Size	• 100 (Raosoft Software)	
Study Population	<ul> <li>Cancer patient adn paediatric oncology (ch</li> </ul>	
Tools	<ul> <li>Data collection forms</li> <li>Questionnaire</li> <li>CDR Request Form</li> </ul>	
<b>Exclusion Criteria</b>	<ul> <li>Patient admitted in the with other indication ophthalmology)</li> </ul>	



### nitted for chemotherapy in nemo) ward only (10B)

### e other ward for chemotherapy (eg: nephrology, neurology,

43

## **STUDY TIMELINE**

**C2** 

### CYCLE 1

August 2023 – January 2024



### VERIFICATION

### February 2023- July 2023

### CYCLE 2

March 2024 – August 2024

## DATA COLLECTION FORM

Doctors:

- Right patient's detail
- **Right protocol**
- Right cytotoxic drug
- Right dose based on BSA and weight
- Right diluent and volume of infusion
- Right concentration of drug
- Right date of preparation

Pharmacist:

- Right patient's detail
- Right protocol
- Right cytotoxic drug
- Right dose based on BSA and weight
- Right diluent and volume of infusion
- Right concentration of drug
- Right date of preparation
- Presence of prescriber's chop and signature

Nurses:

- Right patient's detail
- Right cytotoxic drug
- Right dose
- Right diluent and volume of infusion
- Right routes of administration
- Right infusion rate
- Absence of Leakage or Impurity

Presence of supplied administration set for specific chemo product

## QUESTIONNAIRE

	Questionnaire (Prescriber) Thanks for helping us to fill up the survey =)		Questionnaire (Pharmacists) Thanks for helping to fill up these questions. :)
* lr	ndicates required question	* [r	ndicates required question
1.	Is it easy to fill up the CDR request form? * Mark only one oval.	1.	Email *
	Easy Hard	2.	What criteria should be checked during counterchecking of reconstitu chemotherapy drugs? (Can choose more than one criteria)
2.	Do you require any reference / guideline to fill up the CDR form? * Mark only one oval. Yes No		Check all that apply.   Patient's details  Name of chemotherapy drugs  Final volume of reconstituted chemotherapy drug  Colour and characteristrics chemotherapy drug  Leaking / impurites  Storage and stability Sealed properly
3.	What is the formula of hydration status per hour for pediatric patient (weight > 10 kg)? Mark only one oval. 125ml x BSA 100ml x BSA 125ml x kg	3.	Which reconstituted chemotherapy drug are in red / red orange colou I. Doxorubicin II. Mitoxantrone III. Daunorubicin IV. Idarubicin Mark only one oval. 1 & III 1, III & IV H & IV
	I am not aware of it		<ul> <li>II &amp; IV</li> <li>All of the above</li> </ul>



### Questionnaire (Nurses)

### 1. Which criteria should be checked during counterchecking of chemotherapy?

- I. Correct Patient's details
- II. Correct Drug
- III. Correct Dose

### IV. Correct Date of preparation and date of expiry Ited

V. Correct Colour of drug

### Mark only one oval.

◯ I, III, & IV All of the above

### Which is the criteria for correct drug condition? 2.

### ır? \*

- I. No leaking
- II. No presence of foreign particles
- III. Properly sealed with syringe cap or parafilm

### Mark only one oval.

- All of the above











## RESULTS, ANALYSIS AND INTERPRETATION











### **VERIFICATION STUDY**

### **CDR REQUEST FORM**

### CYTOTOXIC DRUG RECONSTITUTION REQUEST FORM

						DATE	: 13 2 22
NAME:	ALI BIN ABU		MYKID	/ MYKAD:			WARD:
Please [V]: New case	Repeat case			WCH C	012	345	10B
AGE: 4 years	SEX: M /(FI)	WT: L	-5 kg	HT: 99.6	cm	BSA: 0.6	m²
DIAGNÓSIS:	aft Adrenal Neu	ntiastomo					

Chemotherapy	Dose (/m²)	Dose prescribed (infusion/bolus)	Date of PREPARATION*
IV Carboplatin USOMC/45ML	400	20 mg in 100 me NS 2 M 2 m Dol n gon occ	13/2 -
IV Ifosfamida 16/25m	1500	850 mg in 150 me NS 21M	13/2-15/2
IV Stoposide 5 ML	001	60mg in 200 ml NS 3 ML	12/2-15/2-
	Chemotherapy IV Carloplatin USOMC/45ML IV Ifosfamida 16/25ML IV Ifosfamida 16/25ML IV Ifoposida 5ML	ChemotherapyDose (/m²)IV Carlophatin400IV Carlophatin16/25MLIV Ifosfamida16/25MLIV Ifosfamida100ML/ 5ML	Chemotherapy       Dose (/m²)       Dose prescribed (infusion/bolus)         IV Cadopladin       USOMC/\$SML       400       220 mg in 100 ml NS over 1 hm r 22 ML         IV Ifosfamida       16/25 ML       1500       850 Mg in 150 ml NS over 3 hours         IV Ifosfamida       100mc/ 5 ML       100       60 mg in 200 ml NS over 4 hours

### No. of patient on chemotherapy = No. of CDR form received from pharmacy

For Pharmacy Use Pharmacist signature:

Sorang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi di ambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

## Appropriate Management of Chemotherapy Drugs:

- Patient's Details
- Regimen
- Drug
- Dose
- Diluent
- Volume of infusion
- Concentration of drug
- Date of Preparation
- Prescriber's sign and chop



## VERIFICATION





- Total Number of Patient on 674
- Total Number of Patient with Appropriate Management of 515
- **Percentage of Appropriate**

76.4%

## **ACHIEVABLE BENEFIT NOT ACHIEVED (ABNA)**

### Percentage of Appropriate Management of Chemotherapy Drug





## **MODEL OF GOOD CARE**

**Critical step** No.

1

2

### Criteria

Specialist/	CDR request form need to be filled by Specialist include data:
trainee subspecialist prescribing chemotherapy drug	<ul> <li>a) Correct Patient's Details</li> <li>b) Correct Regimen</li> <li>c) Correct Drug</li> <li>d) Correct Dose In Correct Unit (Based On BSA/ Weight)</li> <li>e) Correct Diluent With Its Volume</li> <li>f) Correct Concentration Of Drug</li> </ul>
	Pharmacist screen on received CDR form whether it is a conform with: a) Correct Patient's Details
Pharmacist screen the CDR request form	<ul> <li>b) Correct Regimen</li> <li>c) Correct Drug</li> <li>d) Correct Dose In Correct Unit (Based On BSA/ Weight)</li> <li>e) Correct Diluent With Its Volume</li> <li>f) Correct Concentration Of Drug</li> <li>g) Correct Date Of Preparation</li> <li>h) Presence Of Specialist/Trainee Subspecialist's Chop An</li> </ul>



	Standard	Verification (N=674)
st/ Trainee S	Subspecialist	
	100%	99.4%
	100%	99.0%
	100%	100%
	100%	98.1%
	100%	<b>84.6%</b>
	100%	87.5%
	100%	98.5%
complete CDR		
	100%	99.4%
	100%	100%
	100%	100%
	100%	100%
	100%	100%
	100%	98.1%
	100%	99.5%
nd Signature	100%	99.7% <sub>51</sub>

No.	Critical step	Criteria
3	Prepare CDR worksheet, labels and bags	<ul> <li>Pharmacist or Assistant Pharmacist will prepare:</li> <li>CDR Worksheet: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>Labels: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>e) Correct Patient's Details</li> <li>f) Correct Preparation Date And Expiry Date</li> <li>f) Correct Storage Condition For Record Chemotherapy Drug</li> </ul>
		<ul> <li>Bags:</li> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Number And Size Of Bags Required</li> </ul>

	Standard	Verification (N=674)
	100%	93.0%
	100%	100%
	100%	95.4%
	100%	97.5%
	100%	98.2%
	100%	98.2%
	100%	99.5%
	100%	96.4%
	100%	96.1%
nstituted	100%	99.5%
	100%	99.1%
	100%	98.3%
	100%	95.8%

<b>Io</b> .	Critical step	Criteria	Standard	Verification (N=674)
4	Countercheck CDR worksheet, labels and bags	<ul> <li>Pharmacist will countercheck on the written criteria on:</li> <li>Prepared CDR Worksheet: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>Prepared Labels: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>Prepared Labels: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> <li>e) Correct Diluent With Its Volume</li> <li>e) Correct Preparation Date And Expiry Date</li> <li>f) Correct Storage Condition For Reconstituted Chemotherapy Drug</li> </ul> </li> <li>Prepared Bags: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Drug</li> <li>c) Correct Number And Size Of Bags Required</li> </ul> </li> </ul>	100% 100% 100% 100% 100% 100% 100% 100%	99.5% 100% 100% 99.5% 100% 99.1% 99.5% 100% 99.5% 99.5% 99.5% 99.5%

No.	Critical	step
-----	----------	------

Pharmacist or assistant pharmacist reconstitute the chemotherapy drug with:

Chemotherapy Drug **Reconstitution** 

5

6

- a) Correct Drug
- b) Correct Volume Of Drug
- c) Correct Volume Of Diluent
- d) Absence Of Leakage Or Impurity

Pharmacist countercheck on the reconstituted chemotherapy product by checking on:

Countercheck reconstituted chemotherapy drug and final approve preparation

- a) Correct Patient Details On Label And Bag
- b) Correct Drug
- c) Correct Colour And Its Characteristics
- d) Correct Final Volume
- e) Absence Of Leakage Or Impurity
- Presence Of Supplied Administration Set For f) Specific Chemotherapy Drug

### Standard

### Verification (N=674)

100%
100%
100%
100%

100% 100% 99.4% 96.8%

100%	98.8%
100%	100%
100%	100%
100%	99.9%
100%	99.8%
100%	99.9%

7

8

Nursecheckchemotherapydrugduringcollectionpharmacy

Administer chemotherapy to patient according to regimen and close monitoring Nurse check the reconstituted chemotherapy dru

- a) Correct Patient's Details
- b) Correct Drug
- c) Correct Colour And Characteristics 🕇
- d) Correct Dose
- e) Correct Final Volume ★
- f) Absence Of Leakage Or Impurity ★
- g) Correct Preparation Date And Expiry Date
- h) Correct Storage Condition ★
- i) Presence Of Supplied Administration Set For Chemotherapy Drug

Doctors or nurses will administer chemotherapy the regimen planned with following criteria:

- a) Correct Patient's Details
- b) Correct Drug
- c) Correct Dose And Final Volume Of Reconstitu Chemotherapy Drug
- d) Correct Route Of Administration
- e) Correct Infusion Rate
- f) Correct Date And Time Of Administration
- g) Close Monitor Patient's Vital Sign And Conditi And Post Chemotherapy

	Standard	Verification (N=674)
ig for		
	100%	100%
	100%	100%
	100%	0%
	100%	100%
	100%	14.3%
	100%	<b>28.5</b> %
*	100%	<b>28.5</b> %
	100%	0%
or Specific	100%	0%
according to		
	100%	100%
itad	100%	100%
ited	100%	100%
	100%	100%
	100%	100%
ion During	100%	100%
	100%	100%

### Factors For Low Percentage Of Appropriate Management Of Chemotherapy Drugs



630%	▲ 100.00%	X	100.00%	100.00%
0.0070				90.00%
				80.00%
				70.00%
				60.00%
				50.00%
				40.00%
				30.00%
				20.00%
6	3.70%			10.00%
				0.00%
ue/	Lack of two-ways communication between health care professional	CDR form complica	is too ated	56

## STRATEGIES FOR CHANGE



## **MAIN FINDINGS FOR CONTRIBUTING FACTORS**

### **REMEDIAL CHANGES**

### **CONTRIBUTING FACTOR** PROFESSION

- Build KiddoInfuse

- Lack of knowledge
- Inadequate counterchecking
- Wrong details provided
- **Development Of Quick** Reference
- **Standardized** 3 **Chemotherapy Regimen** 
  - Standardized
  - Chemotherapy Worksheet

- Lack of knowledge •
- Inadequate counterchecking
- Lack of knowledge
- Unfamiliar with prescribing method
- Inadequate counterchecking
- Lack of knowledge

ullet

Wrong details provided

- **Conduct Continuous** Education
- Lack of knowledge

- Specialists /  $\bullet$ **Subspecialists**
- Pharmacists
- Nurses
- Nurses
- Specialists / **Subspecialists**
- **Pharmacists**
- Specialists /  $\bullet$ **Subspecialists**
- Pharmacists lacksquare
- Nurses lacksquare





# 01DEVELOPMENT **OF APP KIDDOINFUSE**



## BEFORE

## INCONSISTENT METHOD OF CALCULATION FOR HYDRATION / CONCENTRATION

Adverse event of chemotherapy
 (eg: haemorrhagic cystitis)
 Infusion-related reaction
 (eg: fever, oedema, flushing, shortness of breath)



## **KIDDOINFUSE**





- Maximum concentration of chemotherapy drug

### **INADEQUATE COUNTERCHECKING**

Volume of diluent for chemotherapy drug

## **AFTER**

## **KIDDOINFUSE**

### ONCALL/EXTENDED: SILE SHUTDOWN

### **Ready-to-use apps:**

✓ Applicable for all chemotherapy drugs (39 drugs) ✓ Can be used by nurses, doctors and pharmacists ✓ Convenient ✓ Work Productivity ✓ Medication error

P201

D. Chipat hear inch





## What is the infusion volume?



## **KIDDOINFUSE**



## Weight: 11kg Height: 79cm **BSA: 0.49m<sup>2</sup>**



### Kiddoinfuse

### Search

### 0.1 to 0.19

\* Only for IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2 \* Do not refer this reference fo...

### 0.2 to 0.24

\* Only for IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2 \* Do not refer this reference fo...

### 0.25 to 0.29

\* Only for IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2 \* Do not refer this reference fo...

### 0.3 to 0.34

\* Only for IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2 \* Do not refer this reference fo...

### 0.35 to 0.39

\* Only for IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2 \* Do not refer this reference fo...

### 0.4 to 0.44

\* Only for IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2 \* Do not refer this reference fo...

### 0.45 to 0.49

\* Only for IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2 \* Do not refer this reference fo...

### SELECT

Title BSA (>10kg)

### **Recommended Volume for 1 hour**

60mL, \*80mL (For IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2)

**Recommended Volume for 2 hour** 100mL

**Recommended Volume for 3 hour** 120mL

**Recommended Volume for 4 hour** 150mL

**Recommended Volume for 6 hour** 250mL

**Recommended Volume for 12 hour** 250mL, 500mL

**Recommended Volume for 24 hour** 250mL, 500mL

### Notes

Do not refer this reference for fixed volume stated in CDR form

Title BSA (>10kg)

Recommended Volume for 1 60mL,

\*80mL (For IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2)

**Recommended Volume for 2 hour** 100mL

**Recommended Volume for 3 hour** 120mL

**Recommended Volume for 4 hour** 150mL

Recommended Volume for 6 hour 250mL

**Recommended Volume for 12 hour** 250mL, 500mL

**Recommended Volume for 24 hour** 250mL, 500mL

Notes

Do not refer this reference for fixed volume stated in CDR form

## **Range of Body Surface Area (BSA) Select Based On Calculated BSA**

Title BSA (>10kg)

### Recommended Volume for 1 hour

60mL. \*80mL (For IV Cyclophosphamide 150 750mg/m2)

Recommended Volume for 2 hour 100mL

Recommended Volume for 3 hour 120mL

Recommended Volume for 4 hour 150mL

Recommended Volume for 6 hour 250mL

Recommended Volume for 12 hour 250mL, 500mL

Recommended Volume for 24 hour 250mL, 500mL

### Notes

Do not refer this reference for fixed volume stated in CDR form

## **Recommended Volume Of Infusion For Each Hour Based On Calculated BSA**

**Customize volume of** infusion based on infusion hour of chemotherapy drug

Title BSA (>10kg)

**Recommended Volume for 1 hour** 

60mL. \*80mL (For IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2)

**Recommended Volume for 2 hour** 100mL

**Recommended Volume for 3 hour** 120mL

**Recommended Volume for 4 hour** 150mL

**Recommended Volume for 6 hour** 250mL

**Recommended Volume for 12 hour** 250mL, 500mL

Recommen 250mL, 500r Remarks

specific drug

### Notes

Do not refer this reference for fixed volume stated in CDR form

### For users to take note on the volume of infusion for Chemotherapy

Title BSA (>10kg)

**Recommended Volume for 1 hour** 60mL. \*80mL (For IV Cyclophosphamide 1500mg/m2 & IV Carboplatin 750mg/m2)

**Recommended Volume for 2 hour** 100mL

120mL



Recommended Volume for 4 hour 150mL

**Recommended Volume for 6 hour** 250mL

Recommended Volume for 12 hour 250mL, 500mL

**Recommended Volume for 24 hour** 250mL, 500mL

Notes Do not refer this reference for fixed volume stated in CDR form



## Recommended Volume for 3 hour Correct volume of diluent (hydration) Correct concentration of chemotherapy

# $\mathbf{02}$ DEVELOPMENT **OF QUICK** REFERENCE

## BEFORE



## REFERENCE DURING COUNTERCHECKING CHEMOTHERAPY DRUGS


# **AFTER**

	WARNA	UBAT SITOTOKSIK	<	S	ORAGE AND STABIL	ITY	
UBAT		WADUL		24 HOURS	STORAGE	48 HOURS	
A .:	WARNA			11 Cytarabine		IV Cyclophosphami	
Actinomycin	Oren			IT Methotrexate		IV Daunorubicin	
DAUNOrubicin	Oron / Moroh	Aller the state of		IV Methotrexate		IV Doxorubicin	
	oren / weran	(ikut kepekatan)	DOS RENDAH DOS TINGGI	Intraventricular		IV Vincristine	
DOXOrubicin	Merah			Methotrexate	Fridge (2-8 °C)		
IDArubicin Oren komorahan		IV Itostamide	- 1110ge (2-0 C)	IV Idarubicin			
DAIUDICIII	rubicin Oren kemerahan		IM L-Asparaginase	4			
Methotrexate	Kuning / Ore	n (ikut kepekatan)	DOS RENDALL DOS TINOS	IV Dacarbazine	_		
Mitomutain	Linear I		(		IV Fludarabine		
wittomycin	Ungu		Statement of the second se	IV Rituximab			
Mitoxantrone	Biru					101101100	
				24 HOURS	STORAGE	48 HOURS	
I hat Sitotoksik se	lain di atas	Tiada warna (Co	lourloss	IV Actinomycin D		IV Mitoxantrone	
obat offotoksik se	ann ur atas	riada warna (Co	nouriess)	IV Carboplatin		IV Cytarabine	
				IV Cisplatin		IV Fluorouracil (5-FU	
	*AT	TENTION*	the second se	IV Etoposide	Room Temperature		
TUNOMAD / D		anna handith BAA		IV Gemcitabine			
TUMOMAB / P	ACLITAXEL	- supply with MA	CRO INFUSION TUBE.	IV Mitoxantrone			
Kindly ook if it i	NOT IN the	nurnla had IMM	EDIATELY TO -)	IV Paclitaxel			

## Colour of Chemotherapy

# Storage and Stability<sub>74</sub>

#### WARNA UBAT SITOTOKSIK

UBAT		WARNA		
Actinomycin	Oren			
<b>DAUNO</b> rubicin	Oren / 🕅	lerah (ikut kepekatan)	DOS RENDAH	DOS TINGGI
<b>DOXO</b> rubicin	Merah			
<b>IDA</b> rubicin	Oren <u>ke</u>	merahan		
Methotrexate	Kuning	<b>Oren</b> (ikut kepekatan)	DOS RENDAH	DOS TINGGI
Mitomycin	Ungu			
Mitoxantrone	<u>Biru</u>			

\*Ubat Sitotoksik selain di atas

Tiada warna (Colourless)

#### STORAGE AND STABILITY

24 HOURS	STORAGE	48 HOURS
IT Methotrexate	•	IV Cyclophosphamide IV Daunorubicin IV Doxorubicin
Intraventricular Methotrexate IV Ifosfamide	Fridge (2-8 °C)	IV Vincristine IV Idarubicin
IM L-Asparaginase IV Dacarbazine		
IV Fludarabine IV Rituximab		

24 HOURS	STORAGE	48 HOURS
IV Actinomycin D		IV Mitoxantrone
IV Carboplatin		IV Cytarabine
IV Cisplatin		IV Fluorouracil (5-FU)
IV Etoposide	Room Temperature	
IV Gemcitabine		
IV Mitoxantrone		
IV Paclitaxel		



## **QUICK REFERENCE**

	-		TORSIK		
UBAT	T		WARNA		1 - 7
Actinomy	iycin O	ren			11
DAUNOru	ubicin O	ren / Merah (ikut kepeka	tan) DOS RENDAH	OS TINGGI	1.00
DOXOru	ubicin M	erah			1 June
IDArub	oicin O	ren kemerahan			1. A.
Methotre	exate K	uning / Oren (ikut kepeka	tan) DOS RENDAH DO	TINGGI	
Mitom	nycin U	ngu			The second
Mitoxan	ntrone B	iru			
	A	di atas	na (Colourless)	1	
At Ph	ask if it is N	not in the purple bag i macy C	Counte	rube.	
At Ph	ask if it is N Dari Dari S	TORAGE AND STABI	ILITY	rube	
BLINATUMO Kindly At Pr 24 Hi IT Cyt	ask if it is N ask if it is N Dari S IOURS tarabine	TORAGE AND STABI	ILITY IV Cyclophosphamide	rube	
BLINATUMO Kindly At Pr 24 Hi IT Cyt IT Mett IV Mett	ask if it is N ask if it is N Dari Dari S OURS tarabine hotrexate	TORAGE AND STABI	ILITY A HOURS IV Cyclophosphamide IV Daunorubicin IV Doxorubicin	rube	
BLINATUMO Kindly At Pr 24 Hi IT Cyt IT Mett Intrave	ask if it is N ask if it is N Dari Dari S DURS tarabine hotrexate thotrexate entricular	TORAGE AND STABI	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine	rube	
BLINATUMO Kindly At Pr 24 Hi IT Cyt IT Meth Intrave Metho IV Ifo	AB / PAG ask if it is N ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin	rube.	
ELINATUMO Kindly At Pr 24 Hi 17 Cyt 17 Meth 10 Meth 10 Meth 10 Meth 10 Meth 10 Meth	AB / PAG ask if it is N ASK ACCOURS Tarabine hotrexate entricular hotrexate entricular hotrexate entricular hotrexate entricular hotrexate entricular hotrexate entricular	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Daunorubicin IV Doxorubicin IV Vincristine IV Idarubicin	rube	
At Photosoft 24 Hi 17 Cyt 17 Mettr 10 Mettro 10 Intrave Methro 10 Intrave 10 Intrave 10 Intrave 10 Intrave	AB / PAC ask if it is N Ask if it is N Antipical Action Ac	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin	r	
ELINATUMO Kindly At Pr 24 Hi IT Cyt IT Meth IV Meth IN L-As IV Dat IV Flu IV Flu	AB / PAC ask if it is N Ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin	rube.	
BLINATUMO Kindly At Provide A Standard At Provide A Standard A Sta	AB / PAC ask if it is N Ask if it is N An An Ask Ask Ask Ask Ask Ask Ask Ask Ask Ask	TORAGE AND STABI STORAGE Fridge (2-8 °C)	AS HOURS	rube.	
ELINATUMO Kindly At Pr 24 Hi IT Cyt IT Meth IV Meth IN L-As IV Dac IV Flu IV Ri IV Ri	AB / PAC ask if it is N Ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) COUNTER IV Cyclophosphamide IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin V Idarubicin IV Idarubicin	rube.	
BLINATUMO Kindly At At A Z4 Hi IT Cyt IT Meth INTrave Metho IV Ifo IM L-As IV Dao IV Flu IV Ri IV Ri IV Ca	AB / PAC ask if it is N Ask if it is	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) COUNTELY ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin 48 HOURS IV Mitoxantrone IV Cytarabine	r	
ELINATUMO Kindly Kindly At Pr 24 H IT Cyt IT Meth IN Too IM L-As IV Dad IV Flu IV Rid IV Ca IV Ca	AB / PAC ask if it is N ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) A MEDIATELY. TQ =) A MEDIATE	r	
ELINATUMO Kindly At At A	AB / PAG ask if it is N ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) COUNTELY ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin 48 HOURS	rube.	
ELINATUMO Kindly At Pr At Pr Z4 Hi IT Cyt IT Meth IN Intrave Metho IV Ifo IM L-As IV Dad IV Flu IV Rid IV Rid	AB / PAG ask if it is N Ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Daunorubicin IV Doxorubicin IV Vincristine IV Idarubicin 48 HOURS IV Idarubicin	r	
BLINATUMO Kindly At Hi IT Cyt IT Meth IV Meth IN Intrave Metho IV Ifo IM L-As IV Dad IV Flu IV Rei IV Ca IV C	AB / PAC ask if it is N ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin V Idarubicin IV Idarubicin IV Idarubicin IV Idarubicin IV Idarubicin IV Fluorouracil (5-FU)	r	
ELINATUMO Kindly Kindly At Pr 24 H IT Cyt IT Meth IN Trave Metho IN L-As IV Dao IV Flu IV Riv IV Riv IV Ca	AB / PAC ask if it is N ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Daunorubicin IV Doxorubicin IV Doxorubicin IV Vincristine IV Idarubicin 48 HOURS IV Mitoxantrone IV Cytarabine IV Fluorouracil (5-FU)	r	
BLINATUMO Kindly At Pr At Pr Z4 Hi IT Cyt IT Meth INTrave Metho IV Ifo IM L-Ass IV Dad IV Flu IV Re IV Ca IV Ca IV C	AB / PAC ask if it is N ask if it is N A A A A A A A A A A A A A A A A A A A	TORAGE AND STABI STORAGE Fridge (2-8 °C)	A MACRO INFUSION MMEDIATELY. TQ =) COUNTELY. TQ =) COUNTELY ILITY 48 HOURS IV Cyclophosphamide IV Daunorubicin IV Daunorubicin IV Daunorubicin IV Doxorubicin IV Dincristine IV Idarubicin IV Idarubicin	r	



Convenient ncrease knowledge Enhance counterchecking process

# 03 **STANDARDIZED** CHEMOTHERAPY REGIMEN

PRESCRIBERS



#### UNIT REKONSTITUSI UBAT SITOTOKSIK (CDR)

JABATAN FARMASI

HOSPITAL TU

#### UNIT REKONSTITUSI UBAT SITOTOKSIK (CDR) **JABATAN FARMASI** PITAL TUNKU AZIZAH **BEFORE – MANUAL FORM** JG RECONSTITUTION **UEST FORM** DATE: DATE: NAME: MYKID/ MYKAD: WARD: URH/ LOB SEX: M/ F/ WT: kg HT: (ひン cm BSA: 0-62m<sup>2</sup> 14 lashe lymphoma / lendenne Pres - protocol it Dose Dose prescribed Date of $(..../m^2)$ (infusion/bolus) **PREPARATION\*** (12/24 (tOB) Lom 0-9 mg in lome cin Som 18mg m Some NS ume 2500 um 1550 unit 014 -11/9/20 U 12-Smp in Smi M3 emo will be prepared and ready by 4.30-5.00pm (Monday-Friday) & 1pm (Saturday, Sunday ed date of preparation.

REQUEST

CYTOTOXIC DRUG F

						LVP	ALC:	
NAME:			MYKID/	MYKAD:				WARD:
Please [V]: New case	Repeat case							
AGE:	SEX: M / F	WT:	kg	HT:	cm	BSA:	n	n <sup>2</sup>
DIAGNOSIS:	-							

No.	Chemotherapy	Dose	Dose prescribed	Date of
		1 1-23	line for a line that has been	DDEDADATIONIÈ
		(/m <sup>*</sup> )	(infusion/bolus)	PREPARATION*

## **240 REGIMENS 45 TYPES OF CANCER**

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan

(Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi di sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 10.00 pagi.

Borang CDR yang diterima selepas jam 10.00 pagi akan diproses & dibancuh pada keesokan harinya.

AGE DIAC	: tyo SNOSIS:/ we lympho
No.	Chemotherapy
,	N martin
2	1 dawnowk
3.	IM pegaspas
4.	17 arethotness
* Pleas	e be informed that c

Sign & Chop. (Consultant/ Specialist/ Medical Officer)

For Pharmacy Use Pharmacist signature:

(Selewat-lewatnya jam 3.00 petang)

No. Keluaran: 01

No. Pindaan: 01

prior to that, please request the chemo to be prepared 1 day earlier.

life (<24hour) post preparation, please liaise with CDR Pharmacist.

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi di sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

#### CYTOTOXIC DRUG RECONSTITUTION **REQUEST FORM** DATE

NANAE			DA			
NAME:		MYKID	/ MYKAD:	WARD:		
				uset 1		
AGE: ADA	SEX: MAR			LOB.		
DIACNOSIC	SLA. IVI FS	VVI: 14 kg	HI: (DV cm	$BSA: \partial - \partial \mathcal{P} m^2$		
aure ly	nphomasic ly	onphonia 1	lencenne Pro	B-protocol it		

No.	Chemotherapy	Dose (/m²)	Dose prescribed (infusion/bolus)	Date of PREPARATION*
,	~ martine	Lomp	0-9 mg in come NOS	07-(12/54 (10B)
2	v daunon bicin	Bomp	18mg in some as	027-1019/54 028-519/54
3.	IM pegaspaseymes	2-500 um	1550 unit	04-819124 075-2219124
4.	17 wethotnessall		is song in smi NS	014 - 119154 035 - 1/10/54
_				. ,
-				

\* Please be informed that chemo will be prepared and ready by 4.30-5.00pm (Monday-Friday) & 1pm (Saturday, Sunday & Public Holiday) on requested date of preparation.

\* If you intend to give chemo prior to that, please request the chemo to be prepared 1 day earlier.

\* For chemo with short shelf life (<24hour) post preparation, please liaise with CDR Pharmacist.

Sign & Chop. (Consultant/ Specialist/ Medical Officer)

For Pharmacy Use Pharmacist signature:

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan (Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi di sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi.

Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

No. Keluaran: 01 No. Pindaan: 01





### **CONSEQUENCES**

- **Choice of Chemotherapy Drug**
- **Details for Chemotherapy** 
  - Dose
- Volume of Diluent Infusion Hour
- **Confusing Writing**

## **IMPACT TO PATIENT**

- **Treatment Outcomes**
- **Medication Error**



## **Collaboration with** DR TEH KOK HOI,

Senior Specialist of **Paediatric Haematology** and Oncology

# **AFTER**

#### CYTOTOXIC DRUG RECONSTITUTION

**REQUEST FORM** 

NAME:		MYKID/ MYKAD:			
Please [v]: New case	Repeat case [				
AGE:	SEX: M / F	WT:	kg	HT:	cm
DIAGNOSIS:					

Acute Lymphoblastic Lymphoma / Leukemia – Protocol HR3

No.	Chemotherapy Dose (/m <sup>2</sup> )		Dose prescr (infusion/bo	Date of PREPARATION	*	
1.	IV Cytarabine	2g	mg in	mL NS	D1	x2
	(4 doses in total)		over 3H <u>BD</u>		D2	x2
2.	IV Etoposide	100mg	mg in	mL NS	D3	x2
			over 2H <u>BD</u>		D4	x2
	(5 doses in total, 12H apart, starting 12H after the last dose of Ara-C)				D5	x1
3.	IM Pegasparaginase	2,500unit	unit		D6	
	(max 3750 unit/dose)	eutes e			( <u>single</u> dose only)	
	Or IM L-Asparaginase	12,500	unit		D6	<u>x2</u>

# Standardised

# **Chemotherapy Regimen**

For Pharmacy Use

Pharmacist signature:

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan (Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi d sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.





#### CYTOTOXIC DRUG RECONSTITUT **REQUEST FORM**

AGE:	E [V]: New case Repeat cas     SEX: M / F	e 🛄 🛛 🛛 WT:	kg HT: cr
Acu	te Lymphoblastic Lympho	oma / Leuke	emia – Protocol <u>HR3</u>
No.	Chemotherapy	Dose	Dose prescribed
		(/m <sup>-</sup> )	(infusion/bolus)
1.	IV Cytarabine (4 doses in total)	2g	mg in mL N over 3H <u>BD</u>
2.	IV Etoposide	100mg	mg in mL N over 2H <u>BD</u>
	(5 doses in total, 12H apart, starting 12H after the last dose of Ara-C)		P
3.	IM Pegasparaginase (max 3750 unit/dose)	2,500unit	unit
	Or IM L-Asparaginase	12,500 unit	unit
4.	IT Methotrexate	age related	mg in 5mL NS
	All chemo are ordered on <u>day of</u> administration except IT MTX		

Sign & Chop. (Consultant/ Specialist/ Medical Officer)

For Pharmacy Use

Pharmacist signature:

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan (Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi ( sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

		П	
IC	1	V	

DATE:

WARD:

# Diagnosis

## Select Based On atient's Diagnosis (single dose only)

x2

y) & 1pm (Saturday, Sunday

arlier.

D6

D1

NAM	1E:		MYKID/ MYKAD:
Pleas	e [v]: New case 📃 Repeat cas	е 🗔	
AGE	: SEX: M / F	WT:	kø HT· r
DIAG	SNOSIS:		
Acu	te Lymphoblastic Lympho	oma / Leuker	
			Cha
Nø.	Chemotherapy	Dose	
		(/111)	
1.	IV Cytarabine	2g	
	(4 doses in total)		n.
2.	IV Etoposide	100mg	
	12H after the last dose of Ara-C)		
3	IM Pegasparaginase	2 500unit	unit -
	(max 3750 unit/dose)	2,000 ame	
	Or IM L-Asparaginase	12,500	
		unit	
4.	IT Methotrexate	age	mg in 5mL NS
		related	
	All chemo are ordered on day of		
	administration except IT MTX		
* Plea	ase be informed that chemo will be	prepared and re	ady by 4.30-5 m (Monda
& Pul	blic Holiday) on requested date of p	preparation.	

Sign & Chop. (Consultant/ Specialist/ Medical Officer)

For Pharmacy Use

Pharmacist signature:

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan (Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi ( sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

ION	
DATE:	
	WARD:
	10B
BSA	m <sup>2</sup>

## motherapy **Jg & Dose**

## Chemotherapy And Dose Based ach Diagnosis & **Patient's Condition**

### **REQUEST FORM**



Sign & Chop. (Consultant/ Specialist/ Medical Officer)

For Pharmacy Use

Pharmacist signature:

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan (Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi ( sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

СҮТОТОХ	(IC DRU) REQU	G REC	ONS <sup>-</sup> M	ΓΙΤυτ
NAME:		MYKID/	MYKAD:	
	- 🗖			
AGE: SEX: M / F		kg	HT:	cm
DIAGNOSIS:				
Acute Lymphoblastic Lympho	oma / Leukei	mia – Prof	tocol <u>H</u>	<u>R3</u>
		-		
No. Chemother			esc	bed
Re Re		KS	17.00	Jius)
1. IV Cytarabi				mL NS
(4 doses in to,			_	
2. La Étoposide	100mg		ng in	mL N
(5 doses in total, 12H apart, starting				
12H after the last dose of Ara-C)				
3. IM Pegasparaginase	2,500unit	u	init	
(max 3750 unit/dose)	12 500		nit	
<u>OI</u> IVI L-Asparaginase	unit	u	init	
4. IT Methotrexate	age	r	ng in 5m	nL NS
	related			
All chemo are ordered on day of				
administration except IT MTX				
* Please sinformed that chemo will be & Public Holiday) on requested date of n	prepared and re preparation.	eady by 4.30-	5.00pm (N	/londay-Frid
* If you intend to give chemo prior to the	at, please reques	t the chemo	to be prep	pared 1 day
* For chemo with short shelf life (<24hou	ur) post preparat	ion, please li	alse with	CDR Pharm

Sign & Chop. (Consultant/ Specialist/ Medical Officer)

For Pharmacy Use

Pharmacist signature:

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan (Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi ( sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

#### ION



## Maximum Dose of chemotherapy drug Frequency of chemotherapy drug Reminder for each ) & 1pm (Saturday, Sunday

## regimen



#### CYTOTOXIC DRUG RECONSTITUT **REQUEST FORM**

NAME:	MYKID/ MYKAD:				
Please [v]: New case	Repeat case [				
AGE:	SEX: M / F	WT:	kg	HT:	cm
DIAGNOSIS: Acute Lymphobla	astic Lymphom	na / Leuker	mia – Pro	tocol <i>H</i>	73

# **Standardised Chemotherapy Regimen:** Convenient Accurate Work Productivity

Sign & Chop. (Consultant/ Specialist/ Medical Officer)

For Pharmacy Use Pharmacist signature:

Borang Permohonan yang lengkap hendaklah dihantar sehari sebelum tarikh sediaan diperlukan (Selewat-lewatnya jam 3.00 petang)

Untuk kes-kes kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi d sambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi. Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

ON	
DATE:	
	WARD:
	10B
BSA:	m <sup>2</sup>

# 04 **STANDARDIZED** CHEMOTHERAPY WORKSHEET

PHARMACISTS

## **BEFORE – MANUAL FORM**

#### KERTAS KERJA REKONSTITUSI UBAT SITOTOKSIK

#### UNIT REKONSTITUSI UBAT SITOTOKSIK, SEKSYEN FARMASI PENGELUARAN JABATAN FARMASI, HOSPITAL TUNKU AZIZAH (HOSPITAL WANITA DAN KANAK-KANAK)

NAMA:	BERAT (kg):	UNIT/WAD:
RN:	TINGGI (cm):	NAMA DOKTOR:
JANTINA:	BSA (m <sup>2</sup> )	
UMUR:	DIAGNOSIS:	

	MAKLUMAT REKONSTITUSI									
Ubat Sitotoksik	Dos (MG)	Bil. Am keku	p/vial & Iatan	Diluent	lsipadu <i>diluent</i>	lsipa Bolus/	adu Infusi			
				AIN				*Sila rujuk Senarai Semak		
								dagangan, pengeluar, nombor kelompok dan		
								tarikh luput produk.		
		HA	HANDVVKITEN							
Disediakan oleh:			Direkons	stitusi oleh:			Disemak	oleh:		
Dibungkus oleh:			Diluluskan oleh:							

#### TARIKH:

## **MANUAL FORM**

KE	RTAS KEF	AJA REK	ONSTITUSI U	BAT SITC	TOKSIK		TARIKH: 13   -	NAM	E Nur Zara Mezya brit	HE MOSCAN	MYKID/ MYKAD:	WARD: 10B
	t's D	etai		OKSIK, S AZIZAH (I	EKSYEN FAR HOSPITAL WA	MASI PENGELUARA ANITA DAN KANAK-	AN KANAK)	AGE: DIAG	4 yours SEX: M/FD NOSIS: Laft Adrenal h	WT:	12-5 kg HT: 99.6 cm	BSA: Q.G m <sup>2</sup>
INAMA: RN: INANTINA	9 A		IBERAT (kg): TINGGI (cm) BSA (m <sup>2</sup> )	:	12.5 99.6 0.6	UNIT/WAD: NAMA DOKTOR:	IO B KO GILAVAN I	No.	Chemotherapy	Dose (/m²)	Dose prescribed (infusion/bolus)	Date of PREPARATION*
UMUR: 4 YR	Strer	ngth	& Qua	ntity	Of ORENA	Volu	ume Of		Carboplation 450mc/\$5ML	400	2N SMOOL NI EM OCL	13/2 -
Ubat Sitotoksik	Che	emot	herapy	/ Dru	<b>g</b> Jiluen	Chemoth	nerapy D	rug	Hostenride 100mc/ 5 mi	100	850 Mg in 150 me NS 21 Mg over 3 hours NS 21 Mg 60 mg in 200 mc NS 3 Mg	13/2-15/2
IN IFOSFAMIDE	1500 mg	i x	16 150 ML		1 x 50 mL	75 m L in 15 N	o ml s				over 4 hours	
	 		5 mL				*Si Ki		IMPACT	TO F	ATIENT	
Misse	d ou	t Of	1 Che	mot	herap	y Drug	r		Treatmer	nt Ou	utcomes	
IV Carboplatin	220 mg	1x	450mg/ 45mL	-	-	22mL in 70mL NS			Medicatio	on Ei	ror	
CLES FARTIA									Wastage	of Cl	hemothera	py
Disediakan oleh:			Direkonstitu Diluluskan o	isi oleh: oleh:		Disema	k ole	Borang F	Permohonan yang lengkap hendaklal t-lewatnya jam 3.00 petang)	n dihantar sehar	i sebelum tarikh sediaan diperlukan	

\*

#### UNIT REKONSTITUSI UBAT SITOTOKSIK (CDR) JABATAN FARMASI HOSPITAL TUNKU AZIZAH

#### CYTOTOXIC DRUG RECONSTITUTION **REQUEST FORM**

					DATE:	13/2/22
- 2ara	Repeat case	° Maso มั	MYKID,	MYKAD:		WARD: 10B
ars	SEX: M /(FI)	WT: 12	-5 kg	HT: 99.6 cm	BSA: 0.6	m <sup>2</sup>
hel	Adrenal New	ablastoma				

kecemasan yang memerlukan persediaan pada hari yang sama, Pegawai Farmasi hendaklah dihubungi di ambungan 1240/1238/1239 dan borang permohonan perlu dihantar sebelum jam 9.00 pagi.

Borang CDR yang diterima selepas jam 9.00 pagi akan diproses & dibancuh pada keesokan harinya.

## AFTER – STANDARDIZED (EXCEL)

#### KERTAS KERJA REKONSTITUSI UBAT SITOTOKSIK

#### UNIT REKONSTITUSI UBAT SITOTOKSIK, SEKSYEN FARMASI PENGELUARAN JABATAN FARMASI. HOSPITAL TUNKU AZIZAH (HOSPITAL WANITA DAN KANAK-KANAK)

NAMA:	BERAT (kg):		UNI
RN:	TINGGI (cm):		NAM
JANTINA:	BSA (m <sup>2</sup> )	0.00	
UMUR:	DIAGNOSIS:	Acute Ly	mphoblastic Ly

		M/	<b>AKLUM</b>	AT REKO	ONSTITUSI		
Ubat Sitotoksik	Dos (MG)	E	Bil. Am keku	⊳/vial & ∎tan	Diluent	lsipadu diluent	
IV Vindesine	0		0	5MG/5M	NS	0 X 5ML	IN
IV Methotrexate	0		0	IG/10ML	Ī		IN
IV Ifosfamide	0		0	IG/25ML	WFI	0 x 25ML	IN
IV Daunorubicin	0		0	20MG/4N	WFI	0 x 4ML	IN
IM Pegasparaginase	0 UNIT		0	3750U/5	ML		
IT Methotrexate	0		0	50MG/21	йL		
				usir	ng exce	l calculato	r
Disediakan oleh:				Direkon	stitusi oleh:	i i	
Dibungkus oleh:				Dilulusk	an oleh:		



#### TARIKH:

T/WAD:	
MA DOKTOR:	
mphoma/Leukemia Protocol HR2	



# 05 CONDUCT CONTINUOUS EDUCATION SESSION



- **Refresh and increase knowledge** on: a) Formula of volume of infusion based on hour
- b) Special precautious each for medication
  - drug



**Continuous Medical Education 'Practice** Make Prefect' was carried out among trainee sub-specialist 10B.

- Available drip in pharmacy
- Storage and expiry of chemotherapy

### Training and demonstration for app

92

**Trainee sub-specialist 10B** attended (100%)



based on hour



**Continuous Medical Education** was carried out among pharmacists and assistant pharmacists

- ✓ Refresh and increase knowledge on: a) Formula of volume of infusion
- b) Criteria to check during
  - counterchecking
- c) Colour, Characteristics, Storage and
  - expiry of chemotherapy drug
- Training and demonstration for app
  - **Pharmacist and Assistant Pharmacist attended**

**Continuous Nursing Education** 'Reginite, Refresh, Renew': For better patient outcome' was carried out among staff nurse 10B

- ✓ Refresh and increase knowledge on: a) Criteria to check during counterchecking of chemotherapy drug
- b) Way to check leaking or particles
- c) Colour and Characteristics of chemotherapy drug

of

- d) Storage and expiry chemotherapy drug
- ✓ Training and demonstration for app



























# EFFECTS OF CHANGE **CYCLE 1**



## **MODEL OF GOOD CARE**

**Critical step** No

	Specialist/ Trainee Subspecialist prescribing chemotherapy drug	<ul> <li>CDR request form need to be filled by specialist/ trainee su</li> <li>a) Correct Patient's Details</li> <li>b) Correct Regimen</li> <li>c) Correct Drug</li> <li>d) Correct Dose In Correct Unit (Based On BSA/ Weight)</li> <li>e) Correct Diluent With Its Volume</li> <li>f) Correct Concentration Of Chemotherapy Drug</li> <li>g) Correct Date Of Preparation</li> </ul>
2	Pharmacist screen the CDR request form	<ul> <li>Pharmacist screen on received CDR form whether it is a complete CDR form with:</li> <li>a) Correct Patient's Details</li> <li>b) Correct Regimen</li> <li>c) Correct Drug</li> <li>d) Correct Dose In Correct Unit (Based On BSA/ Weight)</li> <li>e) Correct Volume Of Diluent</li> <li>f) Correct Concentration Of Chemotherapy Drug</li> <li>g) Correct Date Of Preparation</li> <li>h) Presence Of Specialist/Trainee Subspecialist's Chop And Signature</li> </ul>



Standard	Verification (N=674)	Cycle 1 (N=130)
ubspecialist and	include data:	
100%	99.4%	97.0%
100%	99.3%	100%
100%	100%	100%
100%	98.1%	<b>99.2%</b>
100%	84.6%	<b>94.6%</b>
100%	87.5%	98.5%
100%	98.5%	<b>1</b> 99.2%
4.0.00/		
100%	99.4%	99.2%
100%	100%	100%
100%	100%	100%
100%	100%	100%
100%	100%	100%
100%	98.1%	<b>99.2%</b>
100%	99.5%	100%
100%	99.7%	100%

### No Critical step

### Criteria

3	Prepare CDR worksheet, labels and bags	<ul> <li>Pharmacist or Assistant Pharmacist will prepare:</li> <li>CDR Worksheet: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>Labels: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> </ul> </li> <li>b) Correct Drug</li> <li>c) Correct Dose</li> <li>d) Correct Diluent With Its Volume</li> <li>e) Correct Diluent With Its Volume</li> <li>e) Correct Preparation Date And Expiry Date</li> <li>f) Correct Storage Condition For Reconstituted Chemotherapy Drug</li> </ul> <li>Bags: <ul> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Number And Size Of Bags Required</li> </ul> </li>
---	---	---

Standard	Verification (N=674)	Cycle 1 (N=130)
100% 100% 100% 100%	93.0% 100% 95.4% 97.5%	98.5% 100% 100% 98.5%
100% 100% 100% 100% 100% 100%	98.2% 98.2% 99.5% 96.4% 96.1% 99.5%	<ul> <li>98.5%</li> <li>98.5%</li> <li>99.2%</li> <li>96.2%</li> <li>96.2%</li> <li>100%</li> </ul>
100% 100% 100%	99.1% 98.3% 95.8%	98.5% 98.5% 98.2%

No	Critical step	Criteria
A	Countercheck CDR worksheet, labels and bags	Criteria Pharmacist will countercheck on the written criteria on: Prepared CDR Worksheet: a) Correct Patient's Details b) Correct Drug c) Correct Dose d) Correct Diluent With Its Volume Prepared Labels: a) Correct Patient's Details b) Correct Drug c) Correct Drug c) Correct Dose d) Correct Diluent With Its Volume e) Correct Diluent With Its Volume e) Correct Preparation Date And Expiry Date f) Correct Storage Condition For Reconstituted Chemotherapy Drug Prepared Bags: a) Correct Patient's Details b) Correct Drug
		<ul><li>c) Correct Number And Size Of Bags Required</li></ul>

Standard	Verification (N=674)	Cycle 1 (N=130)
100%	99.5%	99.2%
100%	100%	100%
100%	100%	100%
100%	99.5%	99.2%
100%	99.1%	<b>1</b> 99.2%
100%	100%	100%
100%	100%	100%
100%	99.1%	100%
100%	99.5%	99.2%
100%	100%	100%
100%	99.1%	<b>1</b> 99.2%
100%	99.5%	99.2%
100%	99.5%	99.2%

Pharmacist or assistant pharmacist reconstitute the chemotherapy product with:

#### Chemotherapy

- 5 Drug Reconstitution
- a) Correct Drug
- b) Correct Volume Of Drug
- c) Correct Volume Of Diluent
- d) Absence Of Leakage Or Impurity

Pharmacist countercheck on the reconstituted chemotherapy drug by checking on:

Countercheck reconstituted chemotherapy drug and approve final preparation

- a) Correct Patient Details On Label And Bag
- b) Correct Drug
- c) Correct Colour And Its Characteristics
- d) Correct Final Volume
- e) Absence Of Leakage Or Impurity
- f) Presence Of Supplied Administration SetFor Specific Chemotherapy Drug

6

Standard	Verification	Cycle 1
	(N=674)	(N=130)

100%	100%	100%
100%	100%	100%
100%	99.4%	99.4%
100%	96.8%	<b>1</b> 97.2%

100%	98.8%	<b>1</b> 99.6%
100%	100%	100%
100%	100%	100%
100%	99.9%	<b>100%</b>
100%	99.8%	<b>100%</b>
100%	99.9%	99.8%

7	Nurse check chemotherapy drug during collection in pharmacy	<ul> <li>Nurse check the reconstituted chemotherapy drug for</li> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Colour And Characteristics</li> <li>d) Correct Dose</li> <li>e) Correct Final Volume</li> <li>f) Absence Of Leakage Or Impurity</li> <li>g) Correct Preparation Date And Expiry Date</li> <li>h) Correct Storage Condition</li> <li>i) Presence Of Supplied Administration Set For Specific Chemotherapy Drug</li> </ul>
8	Administer chemotherapy to patient according to regimen and close monitoring	<ul> <li>Doctors or nurses will administer chemotherage according to the regimen planned with following criteriae</li> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose And Final Volume Of Reconstituted Chemotherapy Drug</li> <li>d) Correct Route Of Administration</li> <li>e) Correct Infusion Rate</li> <li>f) Correct Date And Time Of Administration</li> <li>g) Close Monitor Patient's Vital Sign And Condition During And Post Chemotherapy</li> </ul>

	Standard	Verification (N=674)	Cycle 1 (N=130)
	100%	100%	100%
	100%	100%	100%
	100%	0%	<b>69.2</b> %
	100%	100%	100%
	100%	14.3%	<b>100%</b>
	100%	28.5%	100%
	100%	28.5%	<b>61.5%</b>
	100%	0%	<b>46.2%</b>
	100%	0%	<b>100%</b>
ру			
•			
	100%	100%	100%
	100%	100%	100%
	100%	100%	100%
	100%	100%	100%
	100%	100%	100%
	100%	100%	100%
١g	100%	100%	100%
-			

# CYCLE 1



## **CHEMOTHERAPY DRUGS**

**Chemotherapy Drugs** 



**Percentage of Appropriate** Drugs



- Total Number of Patient On 130 **Chemotherapy Drugs**
- Total Number of Patient with 113 Appropriate Management of
- **Management of Chemotherapy**

87.0%

## **ACHIEVABLE BENEFIT NOT ACHIEVED (ABNA)** Percentage of Appropriate Management of Chemotherapy Drug







## What is the strength used

## How long can it be stored

## Can it still be used

## Where to be stored

## What is the colour

## **CHEMOTHERAPY DRUG**





	¢	
Arsenic Trioxide		
Azacitidine		
Bleomycin		
Blinatumomab		
Busulfan		
Carboplatin		
Cisplatin		
Cladribine		
Clofarabine		
Cyclophosphamide		
Cytarabine (Ara-C)		
Dacarbazine		
Daunorubicin		
Dinutuximab		
Doxorubicin (Adriamycin)	SELECT	
Etoposide (VP16)		
Fludarabine		



Red



### Name Of Chemotherapy Drug

### **Colour & Characteristics**



## Use KIDDOINFUSE during counterchecking chemotherapy

# KIDDOINFUSE VERSION 2

1 hour
mide 1500mg/m2 & IV Carboplatin
2 hour
3 hour
4 hour
6 hour
12 hour
24 hour
r fixed volume stated in CDR form

#### 5kg to 5.9kg

 $\heartsuit$ 

Title Weight (<10kg)

Recommended Volume for 1 hour 30 mL \*50mL (for all IV Cyclophosphamide & IV Carboplatin)

**Recommended Volume for 2 hour** 50mL

**Recommended Volume for 3 hour** 80 mL \*80mL (for IV Methotrexate 12000mg/m2)

**Recommended Volume for 4 hour** 100mL

**Recommended Volume for 6 hour** 100 mL

**Recommended Volume for 12 hour** 250mL

**Recommended Volume for 24 hour** 500 mL

#### Notes

Do not refer this reference for fixed volume stated in CDR form

$\heartsuit$

#### 0.45 to 0.49 mg/m2

Title Etoposide

Recommended Volume for 1 hour 150mg/m2 - 180mL

#### **Recommended Volume for 2 hour**

120mg/m2 - 150mL 150mg/m2 - 180mL 200mg/m2 - 250mL

#### **Recommended Volume for 4 hour**

100mg/m2 - 120mL 120 - 125mg/m2 - 150mL 150mg/m2 - 180mL 175mg/m2 - 250mL 300mg/m2 - 400mL

Notes Do not refer this reference for fixed volume st
# **KIDDOINFUSE VERSION 2**

## 1 hour

mide 1500mg/m2 & IV Carboplatin

2 hour

3 hour

4 hour

6 hour

12 hour

24 hour

r fixed volume stated in CDR form

## 5kg to 5.9kg

 $\heartsuit$ 

Title Weight (<10kg)

## Recommended Volume fo

30 mL \*50mL (for all IV Cyclophos

**Recommended Volume fo** 50mL

# WEIGHT **(KG)**

Recommended Volume for 3 h FOT patient 80 mL \*80mL (for IV Methotrexate 12000mg/m2)

**Recommended Volume for 4 hour** 100mL

**Recommended Volume for 6 hour** 100 mL

**Recommended Volume for 12 hour** 250mL

**Recommended Volume for 24 hour** 500 mL

## Notes Do not refer this reference for fixed volume stated in CDR form

0.45 to 0.49 mg/m2

Title Etoposide

 $\heartsuit$ 

**Recommended Volume for 1 hour** 150mg/m2 - 180mL

## **Recommended Volume for 2 hour**

120mg/m2 - 150mL 150mg/m2 - 180mL 200mg/m2 - 250mL

## **Recommended Volume for 4 hour**

100mg/m2 - 120mL 120 - 125mg/m2 - 150mL 150mg/m2 - 180mL 175mg/m2 - 250mL 300mg/m2 - 400mL

Notes Do not refer this reference for fixed volume s

# KIDDOINFUSEVERSION 2

## 0.45 to 0.49 mg/m2

Title Etoposide

**Recommended Volume** 150mg/m2 - 180mL

## **Recommended Volume**

120mg/m2 - 150mL 150mg/m2 - 180mL 200mg/m2 - 250mL

## Recommended Volum

100mg/m2 - 120mL 120 - 125mg/m2 - 150m 150mg/m2 - 180mL 175mg/m2 - 250mL 300mg/m2 - 400mL

Notes Do not refer this referen

# ETOPOSIDE

## **BODY SURFACE** AREA (mg/m2)



## 7kg to 8kg

Title Etoposide

## Recommended Volu

IV Etoposide: Other doses - 150mL 10mg/kg - 200mL

form



## **SOLVE** problem of crystallisation of etoposide based on concentration (<0.4mg/mL)

# **UPDATED KIDDOINFUSE**

r MAXIS	,11 971+22.
	1:
≡ KiddoInfuse	ŧ
All	Title
BSA (>10kg)	0
Weight (<10kg)	0
Etoposide	0
Medication	0
0.4 to 0.44 mg/m2 0.45 to 0.49 mg/m2 0.5 to 0.54 mg/m2	

More precise version Introduce new features and functionality

**Factors:** ✓ Lack of knowledge



# ✓ Inadequate counterchecking

111























# EFFECTS OF CHANGE CYCLE 2



# **MODEL OF GOOD CARE**

**Critical step** No

Criteria

St

Specialist/ Trainee Subspecialist

prescribing 1 chemotherapy drug

> Pharmacist screen the CDR request form

2

CDR request form need to be filled by specialist/ trainee su

- a) Correct Patient's Details
- b) Correct Regimen
- c) Correct Drug
- d) Correct Dose In Correct Unit (Based On BSA/ Weight)
- e) Correct Diluent With Its Volume
- f) Correct Concentration Of Drug
- g) Correct Date Of Preparation

Pharmacist screen on received CDR form whether it is a complete CDR form with:

- a) Correct Patient's Details
- b) Correct Regimen
- c) Correct Drug
- d) Correct Dose In Correct Unit (Based On BSA/ Weight)
- e) Correct Volume Of Diluent
- f) Correct Concentration Of Drug
- g) Correct Date Of Preparation
- h) Presence Of Specialist/Trainee Subspecialist's Chop And Signature



andard	Verification (N=674)	Cycle 1 (N=130)	Cycle 2 (N= 130)			
bspecialis	bspecialist and include data:					
100%	99.4%	97.0%	<b>100%</b>			
100%	99.3%	100%	100%			
100%	100%	100%	100%			
100%	98.1%	99.2%	99.2%			
100%	84.6%	94.6%	<b>97.7%</b>			
100%	87.5%	98.5%	<b>99.1%</b>			
100%	98.5%	99.2%	<b>100%</b>			
100%	99.4%	99.2%	<b>100%</b>			
100%	100%	100%	100%			
100%	100%	100%	100%			
100%	100%	100%	100%			
100%	100%	100%	100%			
100%	98.1%	99.2%	99.2%			
100%	99.5%	100%	100%			
100%	99.7%	100%	100%			

Νο	Critical step	Criteria	Standard	Verification (N=674)	Cycle 1 (N=130)	Cycle 2 (N= 130)
3	Prepare CDR worksheet, labels and bags	Pharmacist or Assistant Pharmacist will prepare: CDR Worksheet: a) Correct Patient's Details b) Correct Drug c) Correct Dose d) Correct Diluent With Its Volume Labels: a) Correct Patient's Details b) Correct Drug c) Correct Dose d) Correct Diluent With Its Volume e) Correct Preparation Date And Expiry Date f) Correct Storage Condition For Reconstituted Chemotherapy Drug Bags: a) Correct Patient's Details b) Correct Drug c) Correct Patient's Details c) Correct Patient's Details c) Correct Drug c) Correct Number And Size Of Bags Required	100% 100% 100% 100% 100% 100% 100% 100%	93.0% 100% 95.4% 97.5% 98.2% 98.2% 99.5% 96.4% 96.1% 99.5%	98.5% 100% 100% 98.5% 98.5% 99.2% 96.2% 96.2% 100%	<ul> <li>100%</li> <li>100%</li> <li>100%</li> <li>100%</li> <li>99.2%</li> <li>100%</li> <li>98.5%</li> <li>97.7%</li> <li>100%</li> <li>98.5%</li> <li>99.2%</li> <li>98.5%</li> <li>99.2%</li> <li>98.5%</li> <li>99.2%</li> <li>98.5%</li> </ul>

Critical	step
	Critical

0	Critical step	Criteria	Standard	Verification (N=674)	Cycle 1 (N=130)	Cycle 2 (N=130)	
		Pharmacist will countercheck on the written					
		criteria on:					
		Prepared CDR Worksheet:					
		a) Correct Patient's Details	100%	99.5%	99.2%	100%	
		b) Correct Drug	100%	100%	100%	100%	
		c) Correct Dose	100%	100%	100%	100%	
		d) Correct Diluent With Its Volume	100%	99.5%	99.2%	<b>100%</b>	
	Countercheck	Prepared Labels:					
	CDR	a) Correct Patient's Details	100%	99.1%	99.2%	99.2%	
	worksheet,	b) Correct Drug	100%	100%	100%	100%	
	labels and	c) Correct Dose	100%	100%	100%	100%	
	bags	d) Correct Diluent With Its Volume	100%	99.1%	100%	100%	
		e) Correct Preparation Date And Expiry Date	100%	99.5%	99.2%	99.2%	
		f) Correct Storage Condition	100%	100%	100%	100%	
		Prepared Bags:					
		a) Correct Patient's Details	100%	99.1%	99.2%	100%	
		b) Correct Drug	100%	99.5%	99.2%	100%	
		c) Correct Number And Size Of Bags Required	100%	99.5%	99.2%	99.2%	

Pharmacist or assistant pharmacist reconstitute chemotherapy product with:

Chemotherapy Drug Reconstitution

5

6

a) Correct Drug
b) Correct Volume Of Drug
c) Correct Volume Of Diluent
d) Absence Of Leakage Or Impurity

Pharmacist countercheck on the reconstituted chemotherapy drug by checking on:

Countercheck reconstituted

- a) Correct Patient Details On Label And Bag
- b) Correct Drug
- c) Correct Colour And Its Characteristics
- d) Correct Final Volume
- e) Absence Of Leakage Or Impurity
- f) Presence Of Supplied Administration SetFor Specific Chemotherapy Drug
- chemotherapy drug and approve final preparation

tandard	Verification (N=674)	Cycle 1 (N=130)	Cycle 2 (N=130)
100%	100%	100%	100%
100%	100%	100%	100%
100%	99.4%	99.4%	100%
100%	96.8%	97.2%	<b>1</b> 99.2%

100%	98.8%	99.6%	<b>100%</b>
100%	100%	100%	100%
100%	100%	100%	100%
100%	99.9%	100%	100%
100%	99.8%	100%	99.2%
100%	99.9%	99.8%	100%

## Criteria

7	Nurse check chemotherapy drug during collection in pharmacy	<ul> <li>Nurse check the reconstituted chemotherapy drug for</li> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Colour And Characteristics</li> <li>d) Correct Dose</li> <li>e) Correct Final Volume</li> <li>f) Absence Of Leakage Or Impurity</li> <li>g) Correct Preparation Date And Expiry Date</li> <li>h) Correct Storage Condition</li> <li>i) Presence Of Supplied Administration Set For Specific Chemotherapy Drug</li> </ul>
3	Administer chemotherapy to patient according to regimen and close monitoring	<ul> <li>Doctors or nurses will administer chemotherapy according to the regimen planned with following criteria:</li> <li>a) Correct Patient's Details</li> <li>b) Correct Drug</li> <li>c) Correct Dose And Final Volume Of Reconstituted Chemotherapy Drug</li> <li>d) Correct Route Of Administration</li> <li>e) Correct Infusion Rate</li> <li>f) Correct Date And Time Of Administration</li> <li>g) Close Monitor Patient's Vital Sign And Condition During And Post Chemotherapy</li> </ul>

tandard	Verification (N=674)	Cycle 1 (N=130)	Cycle 2 (N=130)
100%	100%	100%	100%
100%	100%	100%	100%
100%	0%	69.2%	<b>100%</b>
100%	100%	100%	100%
100%	14.3%	100%	100%
100%	28.5%	100%	100%
100%	28.5%	61.5%	<b>100%</b>
100%	0%	46.2%	<b>100%</b>
100%	0%	100%	100%
100%	100%	100%	100%
100%	100%	100%	100%
100%	100%	100%	100%
100% 100%	100%	100% 100%	100% 100%
100%	100%	100%	100%
100%	100%	100%	100%
<b>TOO</b> /0	100/0	100/0	100/0

# CYCLE 2



- Total Number of Patient on 130
- Total Number of Patient with Appropriate Management of 124
- **Percentage of Appropriate Management of Chemotherapy**

95.4%



# **KNOWLEDGE SURVEY ANALYSIS**



Doctors

Pharmacists





# GOOD FEEDBACKS FROM DOCTORS ON UPDATED KIDDOINFUSE



Kok Hoi Teh 28 Feb to me, Nik, NIK, Koo, Koo ~

Dear Dr Rizal, Nabilah & Kai Tian,

TQ for including me in the QA / QI project for CDR chemo prescribing & preparation. It was great meeting Yee Shen, Alya & Radhika today.

Congrats!

I can see a lot of passion, sweat & sleepless nights spent compiling the chemo prescription app & database! I'm sure our Paeds Onco fellows will be happy to use the app.

And the nurses can get to know the chemo drugs better too.

Thank you to your team for the great effort!















# IMPACT OF PROJECT







122

# **PATIENT SAFETY**





# **WORK PRODUCTIVITY**

Number of Patient = 120 patients / month	Before ( Manual Form )
Time to prescribe chemotherapy drugs for 1 patient	10 minutes
<b>Total Time Use</b> to prescribe chemotherapy drugs for <b>120</b> <b>patients</b>	1200 minutes (~ 2.5 working day
Maximum <b>Time Taken</b> to solve interventions per month:	3 working days



# After (Standardized **Chemotherapy Form + KiddoInfuse App**)

## 5 minutes

**/S**)

600 minutes (~ 1 working day)

1 hour (~ 0.1 working day) 124



## Wrong storage of chemotherapy drugs



Price of c	hemotherapy	preparation
------------	-------------	-------------

Price for chemotherapy medication (range)	RM10.44 to <b>RM 53,277.00</b>
Price of consu	mable:
Personal Protective Equipment (PPE)	RM 150.00
Syringe + Needle (10's)	RM21.50
Others	RM 250.00
Total	RM 53698.50

# **LESSON LEARNT**

✓ TEAMWORK from dedicated discipline

TARGETED REMEDIAL
 ACTION on continuous
 enhancement





# Kiddolnfuse App



≡	KiddoInfuse	£
earch		Title Height -
th to 6 months		
o 12 months		
ear to 2 years		
ears to 3 years		
ears to 4 years		
ears to 12 years	Intro	duce
	New F	eature

## UNIT REKONSTITUSI UBAT SITOTOKSIK (CDR) JABATAN FARMASI HOSPITAL TUNKU AZIZAH

CYTOTOXIC DRUG RECONSTITUTION								
REQUEST FORM								

		_		_		DATE					
NAME:	Opht	ha		<b>M</b> YO E	og	Y	WARD:	l			
Please [v]: New case	🚽 Repeat case 📖					-					
AGE:	SEX: M / F	WT:	kg	HT:	cm	BSA:	m²				
DIAGNOSIS:											
GLAUCOMA (Cvcle: 1 / 2 / 3 / 4 / 5 / 6 )											

No.	Chemotherapy	Dose	Dose prescribed (infusion/bolus)	Date of PREPARATION*
1.	SUBCONJUNCTIVAL MITOMYCIN Strength: 10MG/20ml (0.05%)	0.1mg /0.2ml	Pharmacy preparation: 0.25 mg (0.5ml ) per eye BOLUS *To administer mgl (ml) by opthal team Please select: LEFT eye RIGHT eye BOTH eye	

\* Please be informed that chemo will be prepared and ready by 4.30-5.00pm (Monday-Friday) & 1pm (Saturday, Sunday & Public Holiday) on requested date of preparation.

\* If you intend to give chemo prior to that, please request the chemo to be prepared 1 day earlier.

\* For chemo with short shelf life (<24hour) post preparation, please liaise with CDR Pharmacist.

# **Replication to other discipline in HTA**

Institutions

NAME:

AGE:

No.

1.

2.

З.

DIAGNOSIS:

Please [v]: New case

For Pharmacy Use Pharmacist signature: Stability: \*Mitomycin: 7 days (2-8C)

Sign & Chop. (Consultant/ Specialist/

## UNIT REKONSTITUSI UBAT SITOTOKSIK (CDR) JABATAN FARMASI HOSPITAL TUNKU AZIZAH

## CYTOTOXIC DRUG RECONSTITUTION REQUEST FORM



## OVARIAN BEP (Cycle 1 / 2 / 3 / 4 / 5 / 6 / 7 / 8 / 9/10)

Chemotherapy	Dose (/m²)	Dose prescribed (infusion/bolus)	Date of PREPARATION*				
IV <u>Bleomvsin</u> Day 1 + Day 8 + Day 15	Bolus	30mg bolus	D1 D8 D15				
IV Etoposide Day 1 + Day 2 + Day 3	120mg/ m <sup>2</sup>	mg in 500ml NS over 2 hours	D1 D2 D3				
IV Cisplatin	25 mg/ m <sup>2</sup>	mg in 500ml NS over 1 hour	D1 x 2 D2 x 2				

\* Please be informed that chemo will be prepared and ready by 4.30-5.00pm (Monday-Friday) & 1pm (Saturday, Sunday & Public Holiday) on requested date of preparation.

\* If you intend to give chemo prior to that, please request the chemo to be prepared 1 day earlier.

\* For chemo with short shelf life (<24hour) post preparation, please liaise with CDR Pharmacist.

Sign & Chop. (Consultant/ Specialist/ Medical Officer)

## KEPERLUAN DAN KELULUSAN ICT UNTUK BERKONGSI PENGGUNAAN APPS KIDDOINFUSE KEPADA PUSAT RAWATAN KANSER KANAK-KANAK YANG LAIN D Inbox ×

RIZAL HUSAINI B RAZALI (MOH) <riezal@moh.gov.my> to MALINISHAM, NURKHADIJA, YAM, FARIZAN, RADHIKA, NIK, me, SITI 💌

- বিষ্ Translate to English

Salam sejahtera dan Madani,

Puan Malinishan a/p Subramaniam Cawangan Teknologi Maklumat & Informatik Farmasi Bahagian Dasar & Perancangan Strategik Farmasi Program Perkhidmatan Farmasi, KKM

# **Process on Sharing KiddoInfuse** (Pending for approval from ICT PPF & KKM)

Puan,

Merujuk kepada perkara di atas, pihak kami ingin mendapatkan pencerahan mengenai keperluan dan kelulusan sekiranya Apps KiddoInfuse yang dicipta oleh kakitangan jabatan ini dapat digunapakai dan dikongsikan dengan 8 buah hospital pakar kanser kanak-kanak yang lain.

Terdapat 8 buah Pusat Pakar Rawatan Kanser Kanak-kanak (Pediatrik Hematologi dan Onkologi) di Malaysia termasuk 2 hospital daripada Kementerian Pengajian Tinggi (KPT).

Senarai hospital-hospital tersebut seperti berikut:

- Hospital Pulau Pinang
- 2. Hospital Sultanah Nur Zahirah, Kuala Terengganu
- Hospital Raja Permaisuri Bainun, Ipoh, Perak
- 4. Hospital Sultan Ismail, Johor Bahru
- 5. Hospital Wanita dan Kanak-kanak Likas, Sabah
- Hospital Umum Sarawak
- Pusat Perubatan Universiti Malaya (PPUM)
- 8. Hospital Tunku Ampuan Besar Tunku Aishah Rohani, Hospital Pakar Kanak-kanak UKM (HPKK UKM)

Oleh yang demikian, pihak kami memohon bantuan dan penjelasan lebih lanjut sekiranya terdapat permohonan yang perlu kami majukan untuk kelulusan tersebut.

Bersama-sama email ini disertakan maklumat ringkas berkenaan apps KiddoInfuse untuk Kajian QAQI peringkat HTA yang sedang dijalankan sekarang.

Kerjasama daripada pihak Puan amatlah dihargai.

Sekian, terima kasih

## Institutions

Fri, 22 Mar, 14:43

X

- 🛱

# **List Of Hospitals**



Create another app to educate patient's guardian on information of chemotherapy

# **Patients**Patients p to educate n information



# **Coming Together Is A** BEGINNING



# **Keeping Together Is PROGRESS**

# Working Together Is **SUCCESS**

# ACKNOWLEDGEMENT

ala Lumpur <b>D</b>	ah Hospital Kuala Lumpur Dato' D
nku Azizah	rah Hospital Tunku Azizah <b>Dr Sh</b> a
cist	Senior Pharmacist
icist	Senior Pharmacist
Unit Kualiti (	Unit Kualiti QA HKL
Unit Kualiti C	Unit Kualiti QA HTA



## r. Harikrishna a/l K.Ragavan Nair

## amsul Anuar B Kamarudin

## Ms Tay Chan Yen

## Ms. Gan Shiau Shuang





<b>Plan\Time</b>	Dec 22	Jan 23	Feb 23	Mac 23	Apr 23	May 23	Jun 23	July 23	Aug 23	Sept 23	Oct 23	Nov 23	Dec 23	Jan 24	Feb 24	Mac 24	Apr 24	May 24	Jun 24	July 24	Aug 24	Sept 24	Oct 24
Proposal preparation																							
Data collection (Verification study)																							
Analysis & reporting																							
Remedial actions																							
Data collection & Analysis (Cycle 1)																							
Discussion and Remedial Action																							
(Cycle 2)																							
Data collection & analysis (Cycle 2)																							
Follow up study																							
/ reporting																							
Presentation of results																							
of completed study																							

Plan

Action

# REFERENCES

- Reinhardt H, Otte P, Eggleton AG, Ruch M, Wöhrl S, Ajayi S, et al. Avoiding chemotherapy prescribing errors: 1. Analysis and Innovative Strategies. Cancer. 2019;125(9):1547–57. doi:10.1002/cncr.31950
- Elsaid, K. et al. (2013) "Impact of electronic chemotherapy order forms on prescribing errors at an Urban 2. Medical Center: Results from an interrupted time-series analysis," International Journal for Quality in Health *Care*, 25(6), pp. 656–663. Available at: https://doi.org/10.1093/intqhc/mzt067.
- Ford, C.D. et al. (2006) "Study of medication errors on a Community Hospital Oncology Ward," Journal of 3. Oncology Practice, 2(4), pp. 149–154. Available at: <a href="https://doi.org/10.1200/jop.2006.2.4.149">https://doi.org/10.1200/jop.2006.2.4.149</a>.
- Chua SS, Tea MH, Rahman MH. An observation study of drug administration errors in a Malaysian hospital 4. (study of drug administration errors). J Clin Pharm Ther.2009;34:215-233.10.1111/j.1365-2710.2008.00997.x Chua SS, Chua HM, Omar A. Drug administration errors in paediatric wards: a direct observation approach. 5.
- Eur J Pediatr.2010;169:603-611.10.1007/s00431-009-1084-z
- Ong WM, Suabasyini S. Medication errors in intravenous drug preparation and administration. Med J 6. Malaysia. 2013;63:52-57.
- Collins, C. M., & Elsaid, K. A. (2011). Using an enhanced oral chemotherapy computerized provider order 7. entry system to reduce prescribing errors and improve safety. International journal for quality in health care : Quality the International Society for in Health journal of Care, 23(1), 36-43. https://doi.org/10.1093/intqhc/mzq066



- Ranchon, F., Salles, G., Späth, H. M., Schwiertz, V., Vantard, N., Parat, S., Broussais, F., You, B., Tartas, 8. S., Souquet, P. J., Dussart, C., Falandry, C., Henin, E., Freyer, G., & Rioufol, C. (2011). Chemotherapeutic errors in hospitalized cancer patients: attributable damage and extra costs. BMC cancer, 11, 478. https://doi.org/10.1186/1471-2407-11-478
- Reinhardt, H., Otte, P., Eggleton, A. G., Ruch, M., Wöhrl, S., Ajayi, S., ... & Engelhardt, M. (2019). 9. Avoiding chemotherapy prescribing errors: analysis and innovative strategies. Cancer, 125(9), 1547-1557.
- T.P.G.M. de Vries, R.H. Henning, H.V.Hogerzeil, D.A.Fresle. Guide to good prescribing [Internet]. World 10. Health Organization Action Programme on Essential Drugs Geneva; 2018 [cited 2024 Mar 16]. Available from: https://ephor.nl/wp-content/uploads/2018/12/who-guide-to-good-prescribing-1.pdf
- R. Ashokkumar, Sureshkumar Srinivasamurthy, Scott C Howard [Internet]. Journal of Pharmacology 11. Pharmacotherapeutics 9(2):86-91; 2018 and [cited from: https://www.researchgate.net/publication/327419464 Frequency of chemotherapy medicati on\_errors\_A\_systematic\_review
- Management of Drugs at Health Centre Level. World Health Organization Regional Office of Africa; 12. 2004.
- [Internet]. [cited of Cancer NCI Dictionary terms 13. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chemotherapy

2024 Mar 16]. Available

2024 Apr 21]. Available from: 138